Arulogun Suzanne, Prince H Miles, Gambell Peter, Lade Stephen, Ryan Gail, Eaton Eve, McCormack Christopher
Division of Hematology and Medical Oncology, Department of Pathology, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne, Parkville, Australia.
J Am Acad Dermatol. 2008 Oct;59(4):589-95. doi: 10.1016/j.jaad.2008.05.038. Epub 2008 Jul 24.
Various studies have reported that extracorporeal photopheresis is effective in producing meaningful responses in patients with Sézary syndrome. A single-center, 5-year retrospective analysis was performed on our patients with Sézary syndrome who received extracorporeal photopheresis using a novel protocol. Thirteen patients were treated with extracorporeal photopheresis consistently for a minimum of 2 months. All patients received a modified protocol of one treatment per week for 6 sessions, one session every 2 weeks for 6 sessions, and then one session per month. The overall response rate was 62%: two patients achieved a complete response and 6 patients achieved a partial response. The median time to response was 10 months. The 2- and 4-year predicted overall survivals were 82%. This study was limited by its retrospective nature and small sample size. Response and survival compare favorably with those of previous studies. Our modified treatment protocol appears to produce outcomes similar to the two-day protocol.
多项研究报告称，体外光化学疗法对 Sézary 综合征患者产生有意义的反应有效。我们对采用新方案接受体外光化学疗法的 Sézary 综合征患者进行了一项单中心、为期 5 年的回顾性分析。13 名患者持续接受体外光化学疗法至少 2 个月。所有患者均接受改良方案，即每周进行 1 次治疗，共 6 次；每 2 周进行 1 次治疗，共 6 次；然后每月进行 1 次治疗。总缓解率为 62%：2 例患者达到完全缓解，6 例患者达到部分缓解。缓解的中位时间为 10 个月。2 年和 4 年预测总生存率为 82%。本研究受其回顾性性质和小样本量的限制。缓解率和生存率与先前研究相比具有优势。我们改良的治疗方案似乎产生了与两日方案相似的结果。
